

cytochrome P450 2C8 Antibody (internal region)
Peptide-affinity purified goat antibody
Catalog # AF3610a

Specification

cytochrome P450 2C8 Antibody (internal region) - Product Information

Application	WB
Primary Accession	P10632
Other Accession	NP_000761.3 , NP_001185782.1 , NP_001185783.1 , 1558
Reactivity	Human
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	55825

cytochrome P450 2C8 Antibody (internal region) - Additional Information

Gene ID 1558

Other Names

Cytochrome P450 2C8, 1.14.14.1, CYP11C8, Cytochrome P450 IIC2, Cytochrome P450 MP-12, Cytochrome P450 MP-20, Cytochrome P450 form 1, S-mephenytoin 4-hydroxylase, CYP2C8

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

cytochrome P450 2C8 Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

cytochrome P450 2C8 Antibody (internal region) - Protein Information

Name CYP2C8 {ECO:0000303|PubMed:7574697, ECO:0000312|HGNC:HGNC:2622}

Function

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:<a

[19965576](http://www.uniprot.org/citations/19965576)). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed: [7574697](http://www.uniprot.org/citations/7574697), PubMed: [11093772](http://www.uniprot.org/citations/11093772), PubMed: [14559847](http://www.uniprot.org/citations/14559847), PubMed: [15766564](http://www.uniprot.org/citations/15766564), PubMed: [19965576](http://www.uniprot.org/citations/19965576)). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed: [7574697](http://www.uniprot.org/citations/7574697), PubMed: [15766564](http://www.uniprot.org/citations/15766564), PubMed: [19965576](http://www.uniprot.org/citations/19965576)). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed: [11093772](http://www.uniprot.org/citations/11093772)). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed: [14559847](http://www.uniprot.org/citations/14559847)). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed: [26427316](http://www.uniprot.org/citations/26427316)).

Cellular Location


Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein


cytochrome P450 2C8 Antibody (internal region) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

cytochrome P450 2C8 Antibody (internal region) - Images





AF3610a (0.1 µg/ml) staining of Human Liver lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

cytochrome P450 2C8 Antibody (internal region) - Background

This antibody is expected to recognize all reported isoforms (NP_000761.3; NP_001185782.1; NP_001185783.1). No cross-reactivity with other 2C proteins expected. Reported variants represent identical protein: NP_001185782.1, NP_001185784.1

cytochrome P450 2C8 Antibody (internal region) - References

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, López-Jiménez E, Cascón A, Milne RL, Robledo M, Rodríguez-Antona C. Pharmacogenomics J. 2011 Apr;11(2):121-9. PMID: 20212519